Drug intelligence / Profile preview

NBG-048

Development stage: Unknown
Lead developer: NB Health Laboratory
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NBG-048 is a monoclonal antibody drug candidate developed by NB Health Laboratory. It acts as an inhibitor of chemokines, targeting these signaling proteins to modulate immune responses. The primary therapeutic area under investigation is immune system diseases, with a specific focus on psoriasis. As of the latest available information (February 2025), the drug remains in the discovery phase and has not yet entered clinical trials or received regulatory approval[1][3].

Beyond the preview

Go deeper on NBG-048.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBG-048.

Explore the full profile